In 2017, at San Raffaele Hospital in Milan, Italy, 4-year-old Marco received a hematopoietic stem cell transplant from his father. In the corridor outside the operating room, the transplant team used the most advanced αβTCRT-/CD19 B-cell depletion technology available at the time. Five years later, Marco not only survived but became an active boy playing soccer—one of modern medicine's miracles.
From Dr. Alfred Wiskott's first description of three brothers with a "peculiar infection syndrome" in 1937 to the European Union granting China's Kejin Biotech orphan drug designation for its gene therapy in 2025, humanity's battle against WAS has spanned nearly a century. This transnational, interdisciplinary medical journey represents an epic transformation from despair to hope.
In medical history, certain diseases are named after their discoverers, becoming academic landmarks across time. In 1937, German pediatrician Alfred Wiskott at Munich University Hospital encountered a family: three brothers presented successively with bloody stools, uncontrollable eczema, and recurrent ear infections. He documented it as "hereditary lymphopenic thrombocytopenia"—a simple description that became the starting point for future understanding.
Seventeen years later, American physician Robert Aldrich re-examined such cases. Tracking a Dutch immigrant family with 12 male members, he found 6 died in early childhood from bleeding or infections. Through rigorous pedigree analysis, Aldrich first confirmed an X-linked inheritance pattern, and "Wiskott-Aldrich syndrome" entered medical literature.
The true breakthrough came in 1994. During the early Human Genome Project, Dr. Derry's team used positional cloning to identify the causative gene on the X chromosome short arm (Xp11.22-11.23)—a 9kb DNA sequence containing 12 exons. The encoded 502-amino acid protein, named WAS protein (WASP), became the key to understanding the disease.
WASP serves as a "cytoskeletal architect" in hematopoietic cells. From dendritic cells to platelets, it regulates actin polymerization, influencing immune synapse formation and cell migration. When the WAS gene mutates, this delicate balance breaks, causing thrombocytopenia, immune deficiency, and uncontrolled inflammatory responses.
In the rheumatology/immunology ward at Children's Hospital of Chongqing Medical University, doctors are resuscitating a 2-month-old infant with bloody stools. The baby's neck shows petechial hemorrhages, with a history of eczema and an uncle who died mysteriously at 6 months—classic WAS family clues. Similar scenarios play out globally with diverse presentations:
Infancy: Skin petechiae often the first sign, platelet counts may drop to 10-50×10⁹/L (normal 150-400×10⁹/L), with markedly smaller platelet volume (mean 4.5fL vs normal 7.5fL)
Infections: From pneumococcal pneumonia to PCP and refractory herpes viruses, the infection spectrum is broad and deadly
Immune Storms: ~40% develop autoimmune diseases like autoimmune hemolysis, vasculitis, IgA nephropathy
Cancer Risk: 10%-20% develop lymphoma, especially EBV-associated B-cell lymphoma
Region | Diagnostic Capacity | Treatment Accessibility | 5-Year Survival (%) | Major Research Contributions |
North America/Europe | Genetic testing widely available | HSCT/gene therapy accessible | >90 | International multicenter trials |
China | WASp testing at regional centers | HSCT limited to major cities | 70-80 | Clinical phenotype studies, novel mutations |
Southeast Asia (Vietnam) | Relies on international collaboration | Mainly supportive care | <50 | WAS mutation spectrum establishment |
In 2023, Chongqing Medical University published striking data: Among 165 WAS patients, non-survivors had higher WAS scores (4.1±0.8) than survivors (3.1±1.2). 95% of deaths involved recurrent/severe infections, 25% had intracranial hemorrhage, and irregular IVIG use increased mortality risk 2.86-fold. These numbers reveal a harsh reality: WAS remains highly lethal in resource-limited regions.
Before definitive treatments, physicians fought a "life preservation battle." Supportive care became essential:
· PCP prophylaxis with sulfamethoxazole
· Antivirals like acyclovir for herpes
· IVIG 400-500mg/kg every 2-3 weeks
· Platelet transfusions only for active bleeding
But supportive care is merely "plugging leaks." Chongqing data show 37.5% mortality with supportive care alone. More definitive solutions were urgently needed.
In 1981, University of Minnesota performed the first WAS bone marrow transplant, opening the curative era. As technology advanced, HSCT matured:
From matched sibling to haploidentical donors
Reduced-intensity conditioning regimens
Graft engineering breakthroughs
2025 Italian IPINET data: 71 HSCT patients achieved 75% 25-year survival. Transplantation before age 3 showed significantly better outcomes than delayed procedures.
For patients lacking donors, gene therapy offers an "autologous transplant" revolution. Unlike HSCT, this approach uses patients' own hematopoietic stem cells, genetically corrected ex vivo with viral vectors carrying normal WAS genes.
2015
57th ASH Annual Meeting reported preliminary data: 4 WAS patients receiving lentiviral gene therapy showed platelet recovery and infection resolution at 9-24 months follow-up.
2025
China's Kejin Biotech announced EU orphan designation for CRISPR3.0 gene replacement. Unlike traditional methods, it doesn't simply add genes but precisely edits the mutation site.
As we stand in 2025, WAS management has come far—from desperate supportive care to curative approaches, with survival curves climbing steadily. Yet challenges remain:
>90%
Western survival rates
<50%
Resource-limited regions
100%
New tech 5-year survival
Hope shines through:
Global Networks: IPINET, APID consortium establishing international WAS registries
Novel Therapies: Allosteric stabilizers based on molecular dynamics
Newborn Screening: Flow cytometry for WASp expression becoming available
At Kejin Biotech's lab in Wuxi, scientists are calibrating CRISPR3.0 systems. When asked about their vision, CEO Dr. Haifeng Wang stated: "We aim for one-time treatment, lifetime cure, freeing global WAS patients from donor dependence.
From Dr. Wiskott's three German boys in 1937 to today's gene therapy era, humanity's fight against WAS resembles a century-spanning relay. As medicine transcends borders and lab discoveries become clinical realities, rare disease patients finally move from medicine's periphery to its center—not just a scientific triumph, but a victory for human compassion
© 2025 Hospital Content Marketing Center | Global WAS Syndrome Review
Based on latest international medical research, data current as of July 2025
EN
CN